Skip to main content
Article
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
Arteriosclerosis, Thrombosis and Vascular Biology
  • Karen C Johnson
  • Aaron K Aragaki
  • Rebecca Jackson
  • Alex Reiner
  • Lisa W. Martin, George Washington University
  • Jan Rosing
Document Type
Journal Article
Publication Date
2-1-2016
Inclusive Pages
418-424
DOI
10.1161/ATVBAHA.115.306905
Keywords
  • Activated Protein C Resistance--complications,
  • Coronary Disease--chemically induced,
  • Estrogen Replacement Therapy--adverse effects,
  • Estrogens--adverse effects,
  • Lipoproteins--adverse effects,
  • Progestins--adverse effects
Peer Reviewed
1
Citation Information
Karen C Johnson, Aaron K Aragaki, Rebecca Jackson, Alex Reiner, et al.. "Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy." Arteriosclerosis, Thrombosis and Vascular Biology Vol. 36 Iss. 2 (2016)
Available at: http://works.bepress.com/rebecca_jackson/11/